Nosocomial Infections

Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).

There is a need to improve infectious risk mitigation in adults with diabetes because they are hospitalized for infections between 2.6 and 15.7 times as often as adults without diabetes, depending on the type of infection.